Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung

Model scores of the 29,894 trials active now.

Model score 13% for any early termination, 5% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 22% of the time (1,598 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2020-12-08. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: cancerthe purposepurpose ofcell lungsmall cell
  Phrases that lowered it: the efficacypharmacokineticsevaluate theto evaluatedrugs
• Sponsor's past termination rate: 1.6% (lowers risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Minimum age: 20 (lowers risk) · Who can join
• Trials the sponsor started in the prior 2 years: 35 (lowers risk) · Sponsor's track record
• Phase: 2 (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Has a data monitoring committee: Yes (raises risk) · Design
• Sponsor's past trials: 63 (lowers risk) · Sponsor's track record
• Design: single group (raises risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Drug's FAERS reports with a death: no FAERS history (raises risk) · Drug's FDA history
• Keywords listed: 8 (raises risk) · Design
• Blinding: none (raises risk) · Design
• Responsible party: sponsor (lowers risk) · Design
• Collaborators: 0 (raises risk) · Design
• Number of arms: 1 (raises risk) · Design
• Drug's FAERS reports before start: 0 (lowers risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Phase I/II Trial to Evaluate Safety, Tolerability and Pharmacokinetic Profile of HM61713 in NSCLC Patients NCT01588145 · started 2012 · scored riskier than 36% of active trials completed
• Olmutinib 600 mg QD in Patients With T790M-positive NSCLC After Treatment With an EGFR-TKI NCT04510415 · started 2018 · scored riskier than 24% of active trials terminated
• Phase II Trial to Evaluate the Efficacy and Safety of HM61713 as the 1st-line NSCLC Anticancer Therapy NCT02444819 · started 2015 · scored riskier than 36% of active trials completed
• Clinical Trial of YH25448 in Patients with EGFR Mutation Positive Advanced NSCLC NCT03046992 · started 2017 · scored riskier than 54% of active trials completed
• A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants NCT01900652 · started 2013 · scored riskier than 56% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.